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Devising a strategy for prevention of malaria in pregnant 
women in the Asia Pacific
Malaria in pregnancy is a leading cause of adverse 
pregnancy outcomes in low-income and middle-income 
countries.1 WHO recommends intermittent preventive 
treatment (IPT) with sulphadoxine–pyrimethamine 
in areas of Africa where there is moderate to high 
transmission of Plasmodium falciparum, the most 
prevalent malaria species in the region. However, 
parasite sensitivity to sulphadoxine–pyrimethamine 
is compromised, particularly in parts of east Africa, 
prompting trials of IPT with dihydroartemisinin–
piperaquine.2–4
WHO does not have an equivalent prevention 
strategy for the Asia-Pacific region where we estimate 
(unpublished) that more than 90 million pregnant 
women are at risk of malaria. The epidemiological 
context of the region poses unique challenges. 
Plasmodium vivax infection is characterised by 
unpredictable relapses when hypnozoites emerge 
from dormancy in the liver, and primaquine—the only 
effective treatment against liver-stage infection—is 
contraindicated in pregnancy. P falciparum resistance 
to sulphadoxine–pyrimethamine emerged 40 years ago 
along the Thai–Cambodia border and quickly saturated 
the region,5 two decades before WHO recommended 
its use for IPT in Africa. Malaria transmission intensity is 
diverse, and most mosquito vectors in the Asia-Pacific 
region are exophagic, exophilic, and active in early 
evening, all behaviours that undermine the effectiveness 
of insecticide-treated bednets and indoor residual 
spraying.6 In 2012, Indonesia was the first country in 
the region to implement a strategy of screening and 
treating malaria at the first antenatal visit, with passive 
case management provided thereafter.7
In The Lancet Infectious Diseases, Rukhsana Ahmed 
and colleagues8 report the results of the first IPT study 
in the WHO South-East Asia region, a three-arm, 
open-label, cluster-randomised controlled trial in 
HIV-negative women from Sumba island (site of low 
malaria transmission) and southern Papua (site of 
moderate, year-round, malaria transmission), eastern 
Indonesia. Participants (of any gravidae between 
16 and 30 weeks’ gestation) received either single 
screening with a rapid diagnostic test and treatment 
with dihydroartemisinin–piperaquine if parasitaemic or 
passive case detection to delivery, intermittent screening 
with a rapid diagnostic test at each antenatal visit 
and treatment with dihydroartemisinin–piperaquine 
if parasitaemic, or IPT with dihydroartemisinin–
piperaquine at monthly visits without screening. The 
primary endpoint was malaria infection in the mother at 
delivery.
Malaria prevalence was much lower than expected in 
Sumba, where only one woman of the first 696 tested 
positive by rapid diagnostic test at enrolment in the 
single screening and treatment (SST) and intermittent 
screening and treatment (IST) groups. On the basis of 
these data, the ethics committee in Indonesia suspended 
recruitment in Sumba but allowed researchers to re-
calculate the sample size for Papua to ensure enough 
statistical power. Overall, the intention-to-treat analysis 
showed that malaria prevalence in mothers at delivery 
was 20·2% (128 of 633) in the SST clusters versus 
11·8% (84 of 713) in the IST clusters (relative risk 0·56, 
0·40–0·77; p=0·0005) and 11·6% (61 of 528) in the 
IPT clusters (0·59, 0·42–0·83; p=0·0022). Adjusted 
analysis found IPT to be significantly more effective at 
preventing malaria infections than IST (0·69, 0·48–1·00; 
p=0·050, padjusted=0·0044). These findings suggest that 
monthly dosing with dihydroartemisinin–piperaquine 
might be required to clear new P falciparum and P vivax 
infections and keep relapses of P vivax infection in 
check. A larger trial of IPT is needed to establish whether 
monthly IPT with dihydroartemisinin–piperaquine will 
translate into better birth outcomes relative to SST.
Results from Sumba indicate there is a threshold of 
malaria transmission intensity below which IST and 
IPT with dihydroartemisinin–piperaquine is no more 
protective than SST against malaria and, potentially, 
adverse pregnancy outcomes. By contrast, IPT 
with sulphadoxine–pyrimethamine in Africa remains 
protective against low birthweight even in areas 
where malaria prevalence is extremely low.9 A meta-
regression analysis of IPT studies in Africa was not able 
to detect a cutoff of malaria transmission below which 
sulphadoxine–pyrimethamine no longer protects against 
low birthweight.10 This finding might be explained, 
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in part, by evidence that IPT with sulphadoxine–
pyrimethamine, despite concerning amounts of parasite 
resistance, confers protection against adverse pregnancy 
outcomes among women with malaria, as well as among 
those with curable sexually transmitted infections and 
reproductive tract infections.11 Dihydroartemisinin–
piperaquine alone—as SST, IST, or IPT—is unlikely to 
provide similar dual-protection, although this might 
be inconsequential in Indonesia if co-infection is less 
common than in Africa.12 However, pregnant women 
in Papua New Guinea probably shoulder a dual-burden 
of infection,13,14 similar to their African counterparts.15 
Nonetheless, the evidence presented by Ahmed and 
colleagues is important and shows that IPT with 
dihydroartemisinin–piperaquine might help to shape a 
WHO strategy that protects pregnant women in the Asia-
Pacific region against P falciparum and P vivax infections.
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